BRAF and neoplasm: Haist et al. demonstrated in a retrospective real-world cohort study that in 135 BRAF-mutant melanoma patients, frontline ICI therapy is associated with favorable tumor control and OS vs. frontline targeted therapy (OSm 35 vs. 18 months, p = 0.07), although the difference was not statistically significant (significance was reached in a subgroup of patients without previous systemic treatments, with median OS 41 vs. 14 months, p = 0.02) [49].